-
🔬 Deciphering the Future of RCC Treatment: Prof. Manuela Schmidinger on LITESPARK Studies and HIF-2α Inhibitors
At the recent European Society for Medical Oncology (ESMO) conference, a critical spotlight was on the groundbreaking results of the LITESPARK-003 and LITESPARK-005 studies. Understanding the implications of these studies…
-
🔬 Highlighting TAR-200: Prof. Andrea Necchi’s Perspective on Cancer Treatment Advances
Oncology Frontier brings you an insightful overview of the TAR-200 delivery system, a promising development in cancer therapy, through the lens of Professor Andrea Necchi’s expertise. As a distinguished figure…
-
🔬 Navigating Advanced Prostate Cancer: A Deep Dive with Dr. Silke Gillessen
In the complex and evolving landscape of oncology, understanding advanced prostate cancer is crucial. To shed light on this significant topic, Oncology Frontier had the privilege of interviewing Dr. Silke…
-
AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.
Metabolism-related fatty liver disease (MAFLD) has become the leading cause of global chronic liver disease, yet there are currently no targeted and effective treatments. In recent years, the development of new drugs for MAFLD and metabolism-related fatty liver hepatitis (MASH) has been a mix of optimism and concern. The 2023 American Association for the Study…
-
Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis
Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as of 2019, approximately 296 million people globally suffer from chronic HBV infection, with around 1.5 million new infections annually, leading to 820,000 deaths due to HBV-related complications. Data from the Chinese Center for Disease Control and Prevention…
-
AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention
The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest’s reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern…
-
AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends
The 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) has just concluded in Boston, USA. The team led by Professor Wai-Kay Seto from the University of Hong Kong focused on five research outcomes in the areas of mother-to-child transmission blockage and clinical cure of Hepatitis B, clearance of…
-
Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres
The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University’s Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH)…
Connecting Medical Expertise through Media